Radiomics and Molecular Expression Predictive Model for Esophago-Gastric Junction and Gastric Cancer TRG
NCT ID: NCT04878783
Last Updated: 2024-05-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
138 participants
OBSERVATIONAL
2019-12-20
2027-10-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Quantitative Fluorescent Guided Robotic Surgery for Cancer of the Gastroesophageal Junction
NCT04107623
Accuracy of Indocyanine Green (ICG) Fluorescence Imaging in Tenosynovial Giant Cell Tumor Surgery
NCT07315841
Laparoscopy-assisted and Open Distal Gastrectomy for Gastric Cancer in the Elderly Patients
NCT02246153
Real-time Targeted Fluorescence Endoscopy for Detection of the Primary Cancer Lesion in Patients With a Metastasis of Unknown Primary Tumor in the Head and Neck
NCT06100081
Molecular Fluorescence Endoscopy of (Pre)Malignant Esophageal Lesions
NCT03205501
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A non-good response (non-GR) has shown to be predictable with texture analysis on the pre-treatment CT scan.
Therefore, we hypothesize that texture analysis could let to identify the good response patients.
• To find correlation between the molecular expression of the tumor and the radiomics features.
Texture analysis on the pre-chemotherapy CT scan founded that entropy and compactness were higher and uniformity lower in responders. Nonetheless the association between radiomics features and molecular expression has not been investigated yet.
Therefore, we hypothesize to add some others radiomics signatures to the analysis and to find an association with the molecular expression.
• To find correlation between the molecular expression of the tumor and the TRG.
MSI gastric cancer has been shown to be less responsive to preoperative chemotherapy.
Therefore, we hypothesize to confirm this result.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CT scan
Patients undergoing CT scan staging for gastric and EJ junction cancer + perioperative chemotherapy (FLOT regimen) , CT scan re-staging and radical gastrectomy or esophagogastrectomy will be enrolled in the study
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Preoperative staging: cT2-T4a, cN0-N3, M0.
* Patients \>18 years old.
* Patients undergoing perioperative chemotherapy with Docetaxel, oxaliplatin, leucovorin, and 5-fluorouracil (FLOT).
Exclusion Criteria
* Patients undergoing preoperative radiotherapy.
* Absence of both pre and post-chemotherapy CT-scan.
* Patients with tumor progression during preoperative chemotherapy.
* Patients undergoing other neoadjuvant chemotherapy regimen different from FLOT
* Exploratory laparoscopy with positive cytology on the peritoneal lavage or evidence of peritoneal carcinosis
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Andrea Laghi
UNKNOWN
University of Roma La Sapienza
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Giovanni Maria Garbarino
M.D.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Padova
Padua, , Italy
Link Campus University
Roma, , Italy
Giovanni Maria Garbarino
Roma, , Italy
University of Verona
Verona, , Italy
Amsterdam UMC location University of Amsterdam
Amsterdam, North Holland, Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
URomLS2022
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.